A survey of the clinical experience with dermatan sulfate.
Gianese
F
F
Medical Department, Mediolanum Farmaceutici, Milano, Italy.
Lucchelli
P E
PE
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015844:Heparin Cofactor II / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D011817:Rabbits; D051381:Rats; D006435:Renal Dialysis; D013552:Swine; D013917:Thrombin / Q000378:metabolism; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D003871:Dermatan Sulfate; D015844:Heparin Cofactor II; D013917:Thrombin